Press releases

"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2019.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

Boston Scientific CEO Mike Mahoney will participate in a conference in September 2019. Learn how to join the webcast or watch the replay.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

Physicians will have continued access to the Eluvia™ Drug-Eluting Vascular Stent (DES) System to treat their patients with peripheral artery disease (PAD).

Boston Scientific will participate in an upcoming investor conference in August 2019. A live webcast and replay will be available.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2019. Learn how to tune in.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Boston Scientific shares the FDA’s dedication to providing the best care possible for the 8.5 million patients in the U.S. with peripheral artery disease (PAD).

Data on the Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System were not included in the meta-analyses that were catalysts for the panel meeting.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

Boston Scientific (BSX) will participate in an upcoming investor conference in May 2019. A live webcast and replay will be available.

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

Boston Scientific will participate in the upcoming healthcare conference in May 2019. A live webcast and replay will be available.

New stent system now available for treating patients with deep venous blockages.

Results includes data about Boston Scientific S-ICD, POLARx cryoablation catheter, WATCHMAN device and LUX-Dx insertable cardiac monitor.

Boston Scientific will participate in the upcoming investor healthcare conference in May 2019. A live webcast and replay will be available.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

The inaccessibility of these products will severely limit treatment options for the 50% of women in the U.S. who will suffer from POP during their lives.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2019.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Key data to be featured at European Heart Rhythm Association (EHRA) Congress include outcomes from the LUMINIZE RF balloon catheter for the treatment of AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific will participate in the upcoming healthcare conference in February 2019. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the SVB Leerink healthcare conference in February 2019. A live webcast and replay will be available.

Patient safety is always our highest priority at Boston Scientific.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

All patent litigation between the companies to be dismissed.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q4 ended December 31, 2018. Learn how to tune in.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

A live webcast and replay will be available. Learn how to tune in.

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Boston Scientific will participate in a healthcare investor conference in December 2018. A live webcast and replay will be available.

Boston Scientific will participate in Citi’s healthcare investor conference in December 2018. A live webcast and replay will be available.

In helping care for people living with complex, debilitating and often life-threatening conditions, patient safety is Boston Scientific’s highest priority.

Boston Scientific will participate the healthcare investor conference in November 2018. A live webcast and replay will be available.

Transaction would expand Boston Scientific peripheral interventions portfolio with minimally invasive treatments for cancers and vascular conditions

Boston Scientific will participate in a medtech conference in November 2018. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) will participate in the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, Arizona. Joe Fitzgerald, executive...

"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.

Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.

The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.

Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.

4th annual Connected Patient Challenge focuses on using population health data, patient monitoring or predictive analytics to improve care and lower costs.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2018. Learn how to tune in.

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.

Boston Scientific will participate in the upcoming healthcare conference in September 2018. A live webcast and replay will be available.

Boston Scientific will participate in the upcoming healthcare conference on Sept. 5, 2018. A live webcast and replay will be available.

Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease

Boston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.

Boston Scientific will participate in the upcoming investor conference in August 2018. A live webcast and replay will be available.

"We're excited about the ways our differentiated pipeline will continue to drive our growth," said CEO Mike Mahoney.

Company does not endorse TRC's unsolicited mini-tender offer and recommends stockholders take no action.

Acquisition will add FDA-cleared Sentinel® Cerebral Embolic Protection System to expand Boston Scientific structural heart offerings.

Acquisition to expand Boston Scientific atrial fibrillation (Afib) ablation therapy offerings with innovative cryoballoon platform.

Boston Scientific will webcast its conference call with financial results for Q2 ended June 30, 2018. Learn how to tune in.

Key data to be presented at DDW include five-year outcomes after placement of the WallFlex™ RX Fully Covered Stent System RMV.

Key data will include results for patients treated with LOTUS™ Transcatheter Aortic Valve System and with the Agent™ drug coated balloon.

Boston Scientific will participate in the upcoming investor conference in May 2018. A live webcast and replay will be available.

The CBS network television show “60 Minutes” recently aired a segment with false claims. Read the facts about Boston Scientific pelvic floor products.

Data highlight the successful reduction of inappropriate shocks using the sensing filter in patients implanted with the EMBLEM™ S-ICD System.

Boston Scientific will participate in the upcoming healthcare conference on May 16, 2018. A live webcast and replay will be available.

Acquisition adds Rezūm®, a therapy for patients with symptomatic benign prostatic hyperplasia (BPH).

"Our consistently strong performance reflects our team's ongoing dedication,” said CEO Mike Mahoney.

Data demonstrated safety and effectiveness of VERCISE™ DBS System for controlling Parkinson’s symptoms.

European patent office revokes Edwards Lifesciences '550 patent.

Boston Scientific acquisition launches women's health focus on cancer and may lead to new diagnostic options for ovarian cancer.

Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor

U.K. court affirms that Edwards Lifesciences infringes Boston Scientific patent

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2018. Learn how to tune in.

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia

Data demonstrated RHYTHMIA™ Mapping System, paired with the INTELLAMAP ORION™ Mapping Catheter, safe and effective treatment for a variety of arrhythmias

Boston Scientific will participate in the upcoming healthcare conference on March 27, 2018. A live webcast and replay will be available.

Key data presentations at the European Heart Rhythm Association congress to include results for the RHYTHMIA™ Mapping System and the WATCHMAN™ device.

Boston Scientific will participate in the upcoming healthcare conference on March 27, 2018. A live webcast and replay will be available.

Acquisition expands endoscopic portfolio to include radiofrequency devices

Boston Scientific announced its completed public offering of senior notes.

Boston Scientific announced the pricing of a public offering of senior notes.

"Our team delivered excellent fourth quarter and full year results, said chairman and CEO Mike Mahoney.

Boston Scientific will participate in the upcoming healthcare conference on Feb. 15, 2018. A live webcast and replay will be available.